Guo Shimeng, Zhang Jiandong, Zhang Shuyong, Li Jing
School of life sciences, Shanghai University, Shanghai, China; Chinese Academy of Sciences Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
College of Pharmacy, Nanchang University, Nanchang, China; Chinese Academy of Sciences Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
PLoS One. 2015 Oct 27;10(10):e0141303. doi: 10.1371/journal.pone.0141303. eCollection 2015.
Type 2 Diabetes Mellitus with insulin resistance, pancreatic β cell dysfunction, and hepatic glucose overproduction is increasing in epidemic proportions worldwide. G protein-coupled receptor 40 (GPR40), a clinically proven anti-diabetic drug target, is mainly expressed in pancreatic β cells and insulin-secreting cell lines. Long chain fatty acids (LCFA) increase intracellular calcium concentration and amplify glucose-stimulated insulin secretion by activating GPR40. Here we report that the arginine 104 (R104) is critical for the normal function of GPR40. Mutation of R104 to Proline (R104P) results in complete loss of the receptor function. Linoleic acid, ligand of GPR40, could not elicit calcium increase and ERK phosphorylation in cells expressing this mutant receptor. Further study indicated the R104P mutation reduces cell surface localization of GPR40 without affecting the expression of the protein. The small portion of GPR40 R104P mutant that is still located on the membrane has no physiological function, and does not internalize in response to linoleic acid stimulation. These data demonstrate that R104 in GPR40 is critically involved in the normal receptor functions. Interestingly, R104P is a registered single-nucleotide polymorphism of GPR40. The relationship of this GPR40 variant and type 2 diabetes warrants further investigation.
伴有胰岛素抵抗、胰腺β细胞功能障碍和肝糖过度生成的2型糖尿病在全球正呈流行趋势增加。G蛋白偶联受体40(GPR40)是一个经临床验证的抗糖尿病药物靶点,主要表达于胰腺β细胞和胰岛素分泌细胞系中。长链脂肪酸(LCFA)通过激活GPR40增加细胞内钙浓度并放大葡萄糖刺激的胰岛素分泌。在此我们报告精氨酸104(R104)对GPR40的正常功能至关重要。将R104突变为脯氨酸(R104P)会导致受体功能完全丧失。GPR40的配体亚油酸在表达该突变受体的细胞中无法引发钙增加和ERK磷酸化。进一步研究表明R104P突变降低了GPR40的细胞表面定位,但不影响该蛋白的表达。GPR40 R104P突变体仍位于膜上的一小部分没有生理功能,并且在亚油酸刺激下不会内化。这些数据表明GPR40中的R104关键参与了受体的正常功能。有趣的是,R104P是GPR40的一个已注册的单核苷酸多态性。这个GPR40变体与2型糖尿病的关系值得进一步研究。